Literature DB >> 25378596

Borrelia burgdorferi arthritis-associated locus Bbaa1 regulates Lyme arthritis and K/B×N serum transfer arthritis through intrinsic control of type I IFN production.

Ying Ma1, Kenneth K C Bramwell1, Robert B Lochhead1, Jackie K Paquette1, James F Zachary2, John H Weis1, Cory Teuscher3, Janis J Weis4.   

Abstract

Localized upregulation of type I IFN was previously implicated in development of Borrelia burgdorferi-induced arthritis in C3H mice, and was remarkable due to its absence in the mildly arthritic C57BL/6 (B6) mice. Independently, forward genetics analysis identified a quantitative trait locus on Chr4, termed B. burgdorferi-associated locus 1 (Bbaa1), that regulates Lyme arthritis severity and includes the 15 type I IFN genes. Involvement of Bbaa1 in arthritis development was confirmed in B6 mice congenic for the C3H allele of Bbaa1 (B6.C3-Bbaa1), which developed more severe Lyme arthritis and K/B×N model of rheumatoid arthritis (RA) than did parental B6 mice. Administration of a type I IFN receptor blocking mAb reduced the severity of both Lyme arthritis and RA in B6.C3-Bbaa1 mice, formally linking genetic elements within Bbaa1 to pathological production of type I IFN. Bone marrow-derived macrophages from Bbaa1 congenic mice implicated this locus as a regulator of type I IFN induction and downstream target gene expression. Bbaa1-mediated regulation of IFN-inducible genes was upstream of IFN receptor-dependent amplification; however, the overall magnitude of the response was dependent on autocrine/paracrine responses to IFN-β. In addition, the Bbaa1 locus modulated the functional phenotype ascribed to bone marrow-derived macrophages: the B6 allele promoted expression of M2 markers, whereas the C3H allele promoted induction of M1 responses. This report identifies a genetic locus physically and functionally linked to type I IFN that contributes to the pathogenesis of both Lyme and RA.
Copyright © 2014 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25378596      PMCID: PMC4258437          DOI: 10.4049/jimmunol.1401746

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  80 in total

1.  A critical role for type I IFN in arthritis development following Borrelia burgdorferi infection of mice.

Authors:  Jennifer C Miller; Ying Ma; Jiantao Bian; Kathleen C F Sheehan; James F Zachary; John H Weis; Robert D Schreiber; Janis J Weis
Journal:  J Immunol       Date:  2008-12-15       Impact factor: 5.422

2.  GM-CSF- and M-CSF-dependent macrophage phenotypes display differential dependence on type I interferon signaling.

Authors:  Andrew J Fleetwood; Hang Dinh; Andrew D Cook; Paul J Hertzog; John A Hamilton
Journal:  J Leukoc Biol       Date:  2009-04-30       Impact factor: 4.962

3.  The K/BxN arthritis model.

Authors:  Paul A Monach; Diane Mathis; Christophe Benoist
Journal:  Curr Protoc Immunol       Date:  2008-05

4.  Interval-specific congenic lines reveal quantitative trait Loci with penetrant lyme arthritis phenotypes on chromosomes 5, 11, and 12.

Authors:  Ying Ma; Jennifer C Miller; Hillary Crandall; Eric T Larsen; Diane M Dunn; Robert B Weiss; Meenakumari Subramanian; John H Weis; James F Zachary; Cory Teuscher; Janis J Weis
Journal:  Infect Immun       Date:  2009-06-01       Impact factor: 3.441

Review 5.  Gene expression profiling provides insights into the pathways involved in inflammatory arthritis development: murine model of Lyme disease.

Authors:  Jennifer C Miller; Ying Ma; Hillary Crandall; Xiaohui Wang; Janis J Weis
Journal:  Exp Mol Pathol       Date:  2008-04-08       Impact factor: 3.362

6.  Distinct roles for MyD88 and Toll-like receptors 2, 5, and 9 in phagocytosis of Borrelia burgdorferi and cytokine induction.

Authors:  Ok S Shin; Ralph R Isberg; Shizuo Akira; Satoshi Uematsu; Aruna K Behera; Linden T Hu
Journal:  Infect Immun       Date:  2008-03-31       Impact factor: 3.441

7.  Recognition of Borrelia burgdorferi, the Lyme disease spirochete, by TLR7 and TLR9 induces a type I IFN response by human immune cells.

Authors:  Mary M Petzke; Andrew Brooks; Michelle A Krupna; Dana Mordue; Ira Schwartz
Journal:  J Immunol       Date:  2009-09-30       Impact factor: 5.422

Review 8.  Exploring the full spectrum of macrophage activation.

Authors:  David M Mosser; Justin P Edwards
Journal:  Nat Rev Immunol       Date:  2008-12       Impact factor: 53.106

9.  Regulation of IFN response gene activity during infliximab treatment in rheumatoid arthritis is associated with clinical response to treatment.

Authors:  Lisa Gm van Baarsen; Carla A Wijbrandts; François Rustenburg; Tineke Cantaert; Tineke Ctm van der Pouw Kraan; Dominique L Baeten; Ben Ac Dijkmans; Paul P Tak; Cornelis L Verweij
Journal:  Arthritis Res Ther       Date:  2010-01-22       Impact factor: 5.156

10.  Peripheral blood gene expression profiling in Sjögren's syndrome.

Authors:  E S Emamian; J M Leon; C J Lessard; M Grandits; E C Baechler; P M Gaffney; B Segal; N L Rhodus; K L Moser
Journal:  Genes Immun       Date:  2009-04-30       Impact factor: 2.676

View more
  9 in total

1.  Induction of Interleukin 10 by Borrelia burgdorferi Is Regulated by the Action of CD14-Dependent p38 Mitogen-Activated Protein Kinase and cAMP-Mediated Chromatin Remodeling.

Authors:  Bikash Sahay; Kathleen Bashant; Nicole L J Nelson; Rebeca L Patsey; Shiva Kumar Gadila; Rebecca Boohaker; Ashutosh Verma; Klemen Strle; Timothy J Sellati
Journal:  Infect Immun       Date:  2018-03-22       Impact factor: 3.441

2.  Robust interferon signature and suppressed tissue repair gene expression in synovial tissue from patients with postinfectious, Borrelia burgdorferi-induced Lyme arthritis.

Authors:  Robert B Lochhead; Sheila L Arvikar; John M Aversa; Ruslan I Sadreyev; Klemen Strle; Allen C Steere
Journal:  Cell Microbiol       Date:  2018-10-17       Impact factor: 3.715

3.  MicroRNA Expression Shows Inflammatory Dysregulation and Tumor-Like Proliferative Responses in Joints of Patients With Postinfectious Lyme Arthritis.

Authors:  Robert B Lochhead; Klemen Strle; Nancy D Kim; Minna J Kohler; Sheila L Arvikar; John M Aversa; Allen C Steere
Journal:  Arthritis Rheumatol       Date:  2017-05       Impact factor: 10.995

4.  Functional Variants Associated With CMPK2 and in ASB16 Influence Bovine Digital Dermatitis.

Authors:  Diana Oelschlaegel; Monika Wensch-Dorendorf; Grit Kopke; Roswitha Jungnickel; Benno Waurich; Frank Rosner; Dörte Döpfer; Bertram Brenig; Hermann H Swalve
Journal:  Front Genet       Date:  2022-06-27       Impact factor: 4.772

5.  Genetic Control of Lyme Arthritis by Borrelia burgdorferi Arthritis-Associated Locus 1 Is Dependent on Localized Differential Production of IFN-β and Requires Upregulation of Myostatin.

Authors:  Jackie K Paquette; Ying Ma; Colleen Fisher; Jinze Li; Sang Beum Lee; James F Zachary; Yong Soo Kim; Cory Teuscher; Janis J Weis
Journal:  J Immunol       Date:  2017-10-06       Impact factor: 5.422

6.  The oncoprotein TBX3 is controlling severity in experimental arthritis.

Authors:  Samra Sardar; Alish Kerr; Daniëlle Vaartjes; Emilie Riis Moltved; Edita Karosiene; Ramneek Gupta; Åsa Andersson
Journal:  Arthritis Res Ther       Date:  2019-01-10       Impact factor: 5.156

Review 7.  Lyme arthritis: linking infection, inflammation and autoimmunity.

Authors:  Robert B Lochhead; Klemen Strle; Sheila L Arvikar; Janis J Weis; Allen C Steere
Journal:  Nat Rev Rheumatol       Date:  2021-07-05       Impact factor: 32.286

8.  Antagonistic Interplay between MicroRNA-155 and IL-10 during Lyme Carditis and Arthritis.

Authors:  Robert B Lochhead; James F Zachary; Luciana Dalla Rosa; Ying Ma; John H Weis; Ryan M O'Connell; Janis J Weis
Journal:  PLoS One       Date:  2015-08-07       Impact factor: 3.240

9.  The Cdkn2a gene product p19 alternative reading frame (p19ARF) is a critical regulator of IFNβ-mediated Lyme arthritis.

Authors:  Jinze Li; Ying Ma; Jackie K Paquette; Amanda C Richards; Matthew A Mulvey; James F Zachary; Cory Teuscher; Janis J Weis
Journal:  PLoS Pathog       Date:  2022-03-24       Impact factor: 6.823

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.